Key statistics dashboard for Cytokinetics, Incorporated (CYTK). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Stock Data
| Price | $69.94 |
| Market Cap | $8.7B |
| Enterprise Value | $9.65B |
| Beta | 0.48 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -9.62 |
| Price / Book | -52.83 |
| P/S | 121.68 |
| EV/EBITDA | -11.79 |
| EV/Sales | 135.99 |
| EV/FCF | -16.62 |
| P/FCF | -14.87 |
| Earnings Yield | -9.75% |
| FCF Yield | -6.73% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 84.97% |
| EBIT Margin | -1175.80% |
| EBITDA Margin | -1153.61% |
| Operating Margin | -992.98% |
| Net Margin | -1259.87% |
| Return on Equity | 163.98% |
| Return on Assets | -46.45% |
| Return on Invested Capital | -39.33% |
| Return on Capital Employed | -40.42% |
Financial Health
| Current Ratio | 6.66 |
| Quick Ratio | 6.66 |
| Cash Ratio | 1.41 |
| Debt / Equity | -7.32 |
| Debt / Assets | 66.02% |
| Net Debt / EBITDA | -1.24 |
| Interest Coverage | -5.64 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.99 |
Per-Share Data
| Revenue per share | 0.54 |
| Book Value per share | -1.31 |
| Cash per share | 8.83 |
| FCF per share | -4.40 |
| Tangible Book Value per share | -1.31 |
| Dividend per share | 0.00 |
Related companies: ABVX · AXSM · CORT · CRSP · HALO · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of CYTK: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks